Back to results
US 2019/0218601 A1Published application
Methylated control dna
AssigneeExact Sciences Development Company, LLC
InventorsHatim T. Allawi, Graham P. Lidgard
Life of this patent
Estimating the term…
Abstract
Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.
Claims27
A composition, comprising:
- a complex of a bisulfite-converted B3GALT6 nucleic acid and at least one oligonucleotide, wherein at least a portion of said oligonucleotide is hybridized to said B3GALT6 nucleic acid.
A kit, comprising:
- a) at least one oligonucleotide, wherein at least a portion of said oligonucleotide specifically hybridizes to bisulfite-converted B3GALT6 DNA;
- and
- b) bisulfite reagent.
A method of characterizing a sample, the method comprising:
- a) treating DNA from a sample with a bisulfite reagent to produce bisulfite-converted DNA;
- b) amplifying a region of said bisulfite-converted DNA using a pair of nucleic acid primers, wherein said amplifying produces amplified product having a sequence comprising a region of SEQ ID NO:2.
A method of characterizing a sample, comprising:
- a) treating DNA from a sample from a subject with a bisulfite reagent to produce a bisulfite-treated DNA sample;
- b) measuring an amount of at least one bisulfite-converted methylation marker DNA in the bisulfite-treated DNA sample;
- c) measuring an amount of bisulfite-converted B3GALT6 DNA in the bisulfite-treated DNA sample;
- and
- d) comparing the amount of said at least one bisulfite-converted methylation marker DNA and the amount of bisulfite-converted B3GALT6 DNA in the bisulfite-treated DNA sample to determine an amount of the at least one methylation marker DNA in said sample from a subject.
2 more elements
A method of quantitating, in a blood sample from a subject, the amount of a methylated marker DNA that is indicative of a tumor in a solid tissue, the method comprising:
- a) measuring an amount of a methylated first marker DNA in a blood sample from a subject, wherein methylation of said first marker DNA in a solid tissue in a subject is indicative of a tumor in said tissue;
- b) measuring an amount of a methylated second marker DNA in said blood sample, wherein said second marker DNA is methylated in normal tissue and in leukocytes;
- and
- c) comparing the amounts of said methylated first marker DNA and said methylated second marker DNA in said blood sample to determine a fraction of said first marker DNA in said blood sample that is methylated.
1 more element
Dependencies are inferred from the claim text.